Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study

The Lancet Global Health

Volumn 4, Issue 8, 2016, Pages e559-e567

  Lemoine, Maud ^a,b   Shimakawa, Yusuke ^a,c   Njie, Ramou ^d   Taal, Makie ^e   Ndow, Gibril ^a,b   Chemin, Isabelle ^f   Ghosh, Sumantra ^f   Njai, Harr F ^a   Jeng, Adam ^a   Sow, Amina ^g   Toure Kane, Coumba ^g   Mboup, Souleymane ^g   Suso, Penda ^a   Tamba, Saydiba ^a   Jatta, Abdullah ^a   Sarr, Louise ^a   Kambi, Aboubacar ^a   Stanger, William ^b   Nayagam, Shevanthi ^b   Howell, Jessica ^b   Mpabanzi, Liliane ^h,i,j   Nyan, Ousman ^k   Corrah, Tumani ^a   Whittle, Hilton ^l   Taylor Robinson, Simon D ^b   D'Alessandro, Umberto ^a   Mendy, Maimuna ^d   Thursz, Mark R ^b   more..

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b ST MARY S HOSPITAL   (United Kingdom)

^c INSTITUT PASTEUR   (France)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^e MINISTRY OF HEALTH AND SOCIAL WELFARE   (Gambia)

^f CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^g Centre Hospitalier Universitaire Aristide Le Dantec de Dakar   (Senegal)

^h MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ MAASTRICHT UNIVERSITY   (Netherlands)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k Royal Victoria Teaching Hospital Gambia   (Gambia)

^l LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BLOOD DONOR; COMMUNITY ASSESSMENT; COUNSELING; ENZYME IMMUNOASSAY; FEASIBILITY STUDY; FEMALE; HEALTH PROGRAM; HEPATITIS B; HUMAN; KNOWLEDGE; LIVER FIBROSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEOPLASM; POINT OF CARE TESTING; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; VIRUS INFECTION; WORLD HEALTH ORGANIZATION; YOUNG ADULT; AGE; BLOOD; COMMUNICABLE DISEASE; CONTROLLED STUDY; GAMBIA; HEPATITIS B VIRUS; IMMUNOLOGY; LIVER CIRRHOSIS; MASS SCREENING; POINT OF CARE SYSTEM; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SEX FACTOR;

ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN;

ADULT; AGE FACTORS; ANTIVIRAL AGENTS; BLOOD DONORS; COMMUNICABLE DISEASES; FEASIBILITY STUDIES; FEMALE; GAMBIA; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LIVER CIRRHOSIS; MALE; MASS SCREENING; MIDDLE AGED; POINT-OF-CARE SYSTEMS; PREVALENCE; SEX FACTORS;

EID: 84991678389     PISSN: None     EISSN: 2214109X     Source Type: Journal    
DOI: 10.1016/S2214-109X(16)30130-9     Document Type: Article

References (35)

1. 1 Schweitzer, A, Horn, J, Mikolajczyk, RT, Krause, G, Ott, JJ, Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 386 (2015), 1546–1555.
2. 2 Kirk, GD, Lesi, OA, Mendy, M, et al. The Gambia Liver Cancer Study: infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology 39 (2004), 211–219.
3. 3 WHO-UNICEF estimates of HepB3 coverage. http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragehepb3.html (accessed June 15, 2015).
4. 4 Locarnini, S, Hatzakis, A, Chen, DS, Lok, A, Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs. J Hepatol 62:suppl 1 (2015), S76–S86.
5. 5 WHO. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection, 2015, World Health Organization, Geneva http://who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/ (accessed March 17, 2015).
6. 6 Thursz, M, Cooke, GS, Hall, AJ, Hepatitis B treatment in resource poor settings: time for action. Trop Med Int Health 15 (2010), 2–4.
7. 7 Lemoine, M, Thursz, M, Njie, R, Dusheiko, G, Forgotten, not neglected: viral hepatitis in resource-limited settings, recall for action. Liver Int 34 (2014), 12–15.
8. 8 Allain, JP, Opare-Sem, O, Sarkodie, F, Rahman, R, Owusu-Ofori, S, Deferred donor care in a regional hospital blood center in Ghana. Transfusion 49 (2009), 669–675.
9. 9 Kiire, CF, The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa. Gut 38:suppl 2 (1996), S5–12.
10. 10 PROLIFICA - West African Treatment Cohort for Hepatitis B (WATCH). https://clinicaltrials.gov/ct2/show/NCT02129829 (accessed March 15, 2015).
11. 11 Andermann, A, Blancquaert, I, Beauchamp, S, Dery, V, Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 86 (2008), 317–319.
12. 12 Njai, HF, Shimakawa, Y, Sanneh, B, et al. Validation of rapid point-of-care (POC) tests for detection of hepatitis B surface antigen in field and laboratory settings in the Gambia, Western Africa. J Clin Microbiol 53 (2015), 1156–1163.
13. 13 Lemoine, M, Shimakawa, Y, Nayagam, S, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. Gut, 2015, 10.1136/gutjnl-2015-309260 published online June 24.
14. 14 Shimakawa, Y, Lemoine, M, Njai, HF, et al. Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia. Gut, 2015, 10.1136/gutjnl-2015-309892 published online July 16.
15. 15 Whittle, HC, Inskip, H, Hall, AJ, Mendy, M, Downes, R, Hoare, S, Vaccination against hepatitis B and protection against chronic viral carriage in The Gambia. Lancet 337 (1991), 747–750.
16. 16 Lemoine, M, Shimakawa, Y, Njie, R, et al. Food intake increases liver stiffness measurements and hampers reliable values in patients with chronic hepatitis B and healthy controls: the PROLIFICA experience in The Gambia. Aliment Pharmacol Ther 39 (2014), 188–196.
17. 17 Boursier, J, Zarski, JP, de Ledinghen, V, et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 57 (2013), 1182–1191.
18. 18 Ghosh, S, Sow, A, Guillot, C, et al. Implementation of an in-house quantitative real-time polymerase chain reaction method for Hepatitis B virus quantification in West African countries. J Viral Hepat, 2016, 10.1111/jvh.12561 published online June 29.
19. 19 EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57 (2012), 167–185.
20. 20 Morisky, DE, Green, LW, Levine, DM, Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24 (1986), 67–74.
21. 21 Koh, C, Zhao, X, Samala, N, Sakiani, S, Liang, TJ, Talwalkar, JA, AASLD clinical practice guidelines: a critical review of scientific evidence and evolving recommendations. Hepatology 58 (2013), 2142–2152.
22. 22 van der Sande, MA, Waight, P, Mendy, M, et al. Long-term protection against carriage of hepatitis B virus after infant vaccination. J Infect Dis 193 (2006), 1528–1535.
23. 23 Peto, TJ, Mendy, ME, Lowe, Y, Webb, EL, Whittle, HC, Hall, AJ, Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986–90) and in the nationwide immunisation program. BMC Infect Dis, 14, 2014, 7.
24. 24 Chamie, G, Kwarisiima, D, Clark, TD, et al. Uptake of community-based HIV testing during a multi-disease health campaign in rural Uganda. PLoS One, 9, 2014, e84317.
25. 25 González, R, Munguambe, K, Aponte, J, et al. High HIV prevalence in a southern semi-rural area of Mozambique: a community-based survey. HIV Med 13 (2012), 581–588.
26. 26 Cook, J, Xu, W, Msellem, M, et al. Mass screening and treatment on the basis of results of a Plasmodium falciparum-specific rapid diagnostic test did not reduce malaria incidence in Zanzibar. J Infect Dis 211 (2014), 1476–1483.
27. 27 Mills, EJ, Nachega, JB, Buchan, I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 296 (2006), 679–690.
28. 28 Marcellin, P, Zoulim, F, Hezode, C, et al. Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B: a 3-year, prospective, real-world study in France. Dig Dis Sci, 2016, 10.1007/s10620-015-4027-8 published online Jan 28.
29. 29 WHO. Global database on blood safety. http://www.who.int/bloodsafety/global_database/en/ (accessed Jan 5, 2015).
30. 30 Bottero, J, Boyd, A, Gozlan, J, et al. Performance of rapid tests for detection of HBsAg and anti-HBsAb in a large cohort, France. J Hepatol 58 (2013), 473–478.
31. 31 Feret, E, Larouze, B, Diop, B, Sow, M, London, WT, Blumberg, BS, Epidemiology of hepatitis B virus infection in the rural community of Tip, Senegal. Am J Epidemiol 125 (1987), 140–149.
32. 32 Dusheiko, GM, Brink, BA, Conradie, JD, Marimuthu, T, Sher, R, Regional prevalence of hepatitis B, delta, and human immunodeficiency virus infection in southern Africa: a large population survey. Am J Epidemiol 129 (1989), 138–145.
33. 33 Beckett, GA, Ramirez, G, Vanderhoff, A, et al. Early identification and linkage to care of persons with chronic hepatitis B virus infection—three U.S. sites, 2012–2014. MMWR Morb Mortal Wkly Rep 63 (2014), 399–401.
34. 34 O'Leary, MC, Sarwar, M, Hutchinson, SJ, et al. The prevalence of hepatitis C virus among people of South Asian origin in Glasgow—results from a community based survey and laboratory surveillance. Travel Med Infect Dis 11 (2013), 301–309.
35. 35 Nayagam, S, Conteh, L, Sicuri, E, et al. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis. Lancet Glob Health 4 (2016), e568–e578.